In contrast, encorafenib activates ERK1/2 signalling (via the RAF paradox [12]) and promotes compensated cardiac hypertrophy in a similar manner to knock-in of the BRAF(V600E) mutation [16]. This evidence concerns the gene MAPK3 and cardiac hypertrophy.